Brief: MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
07/11/2025 14:07
Nov 7 (Reuters) - Mink Therapeutics Inc INKT.O: MINK THERAPEUTICS REPORTS DURABLE RESPONSES AND IMMUNE REACTIVATION WITH ALLO-INKT CELL THERAPY AGENT-797 IN PD-1–REFRACTORY SOLID TUMORS AT SITC 2025 MINK THERAPEUTICS INC - AGENT-797 WELL TOLERATED ACROSS ALL TREATED PATIENTS Source text: ID:nGNX70C6Tc Further company coverage: INKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mink Therapeutics
See all newsMiNK Therapeutics Q2 loss narrows on expense discipline
Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's